The recent success of experimental mRNA vaccines against pancreatic cancer and melanoma has offered real hope for patients facing dire prognoses. Fewer than 1 in 7 pancreatic cancer patients survive five years after diagnosis, yet an early trial showed that most patients whose immune systems responded remained alive years later. A related vaccine nearly halved the risk of melanoma recurrence. After years of false starts, this progress appears genuine.
But even as researchers celebrate these advances, Washington is moving to dismantle the research foundation that made them possible. On May 29, the Office of Management and Budget proposed a rule that would reshape how every federal science agency awards and manages research grants. The public has until July 13 to comment before it takes effect October 1.
The rule requires political appointees to approve funding decisions, reduces scientific peer review to mere advice that agencies can disregard, and allows the government to cancel already awarded grants if projects are deemed “no longer in the federal government’s interest.” The administration frames this as “accountability,” but critics argue it injects politics directly into science.
Setting broad national research priorities is a legitimate role for elected leaders. This rule, however, goes further by handing decisions that once belonged to scientists to appointees accountable to a political agenda. The consequences are already visible: the same leadership promoted vitamin A during a measles outbreak, leading to hospitalized children with vitamin A toxicity. That is not the judgment voters want deciding which cancer trials deserve funding.
It is true that companies like BioNTech, Genentech, Moderna, and Merck developed these cancer vaccines. But they built on decades of federally funded discovery in RNA and immunology—the science that earned the 2023 Nobel Prize in medicine—and on a workforce trained in university labs sustained by public grants. The personal stakes of cancer research are underscored by stories like Jill Biden's revelation of her husband's diagnosis.
The government has already turned against parts of this platform. In August, it canceled 22 mRNA vaccine projects worth nearly $500 million aimed at the next pandemic, with Health and Human Services Secretary Robert F. Kennedy Jr. calling mRNA more risk than benefit. The evidence does not support that claim.
The proposed rule would not immediately cancel industry trials, but the damage is slower and deeper: it weakens the public base from which the next generation of cancer vaccines will grow. You do not kill a field in a single stroke; you defund its base, stigmatize its tools, and hand the next decision to politics.
The 2026 budget request would cut the National Cancer Institute by roughly 37 percent. The rule would let an appointee, not a panel of scientists, decide which cancer trials live or die. Public figures like former Attorney General Pam Bondi have also shared their cancer battles, highlighting the widespread impact of such funding decisions.
Last spring, the National Cancer Institute froze a $7 million grant to a Harvard breast cancer laboratory—not over scientific quality, but because the administration froze Harvard’s research funding over campus antisemitism. The lab lost one-third of its staff before the money was restored months later. Under the proposed rule, such freezes would be far easier to justify as a shift in government priorities rather than scientific merit.
The U.S. cancer death rate has fallen by one-third since 1991. That progress came from a long, patient bet on research that pays off over decades—the same bet that produced the vaccine now giving pancreatic cancer patients years they would not otherwise have. The people celebrating that result are standing inside the return on money spent before most were diagnosed. The proposed rule would stop us from spending it for the patients still to come.
Congress controls appropriations and can refuse the cut to the National Cancer Institute. The rule is open for public comment until July 13. Scientists, universities, and patients can object to language that makes peer review optional and lets the government drop awarded grants on shifting political grounds. The wall between politics and peer-reviewed science is not bureaucratic housekeeping. It produced the breakthrough we are all cheering, and it is worth defending while there is still time to say so.
